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Impact of renal insufficiency on clinical outcomes
in patients with critical limb ischemia undergoing
endovascular revascularization
Torsten Willenberg, MD, Frederic Baumann, MD, Ute Eisenberger, MD, Iris Baumgartner, MD,
Dai-Do Do, MD, and Nicolas Diehm, MD, Bern, Switzerland
Background: Patients with renal insufficiency (RI) are frequently excluded from trials assessing various endovascular
revascularization concepts in critical limb ischemia (CLI) although information on clinical outcomes is scarce.
Methods: Consecutive patients with CLI undergoing endovascular lower limb revascularization during a 4.5-year time
interval at a tertiary referral center were prospectively followed over a 12-month period. Patients were grouped according
to renal function defined as normal (estimated glomerular filtration rate [eGFR] > 60 mL/min/1.73 m2; n  108,
49.5%), moderate RI (eGFR > 30-59 mL/min/1.73 m2; n  86, 39.5%) and severe RI, including dialysis (eGFR < 30
mL/min/1.73 m2; n  24, 11%). Clinical endpoints assessed were sustained clinical success, peri- and postprocedural
mortality and major, above-the-ankle amputation. Sustained clinical improvement was defined as an upward shift of at
least one category on the Rutherford classification compared with baseline to a level of claudication without repeated
revascularization or unplanned amputation in surviving patients. Survival analysis was performed using the Kaplan–
Meier method. Multivariate regression analysis was conducted in separate models for all above-mentioned clinical
endpoints.
Results: A total of 208 patients (218 limbs, mean age 77.1  9.5, 131 men) underwent endovascular revascularization.
Technical success rate was 95.2%, 92.5%, and 100% in patients without, moderate or severe RI. Sustained clinical success
was 81.7%, 74.1%, and 51.5% in patients with normal renal function, 87.8%, 67.0%, and 63.3% with moderate, and
81.0%, 64.6%, and 50.2% with severe RI (P  .87 by log-rank) at 2, 6, and 12 months. Accordingly, major amputation
rates were 9.9%, 18.2%, and 20.8% vs 9.9%, 22.6%, and 24% vs 12.5%, 16.7%, and 21.1% (P .83, by log-rank). Mortality
rates were 8.4%, 17.6%, and 26.5% in patients with normal renal function, 9.6%, 17.6%, and 30.1% with moderate and
17.5%, 26.6%, and 31.9% in patients with severe RI (P  .77, by log-rank) at corresponding intervals. Multivariate
analysis revealed eGFR (hazard ratio [HR], 1.016; 95% confidence interval [CI], 1.001-1.031; P .036), age (HR, 1.12;
95% CI, 1.061-1.189; P< .0001) and cigarette smoking (HR, 3.14; 95% CI, 1.153-8.55; P .026) to be predictors for
increased mortality within 1 year of follow-up.
Conclusion:While functional lower limb outcomes were not influenced by renal function in this study, presence of RI was
an independent predictor for higher mortality in CLI patients undergoing endovascular revascularization. (J Vasc Surg
2011;53:1589-97.)
t
a
l
t
e
e
i
f
b
c
a
f
e
e
c
i
PRenal insufficiency (RI) is associated with critical limb
ischemia (CLI) affecting a subgroup of patients suffering from
a particularly severe form of peripheral arterial disease (PAD)
that causes ischemic rest pain and tissue loss.1-3 CLI is associ-
ated with excess morbidity and mortality rates and leads to a
significant decline in quality of life.2,3 CLI patients not under-
going arterial revascularization were shown to face mortality
and amputation rates as high as 54% and 46%, after 12
months.2 In contrast, CLI patients undergoing successful
revascularization were shown to survive longer and have an
increased quality of life compared with patients receiving best
medical treatment only or primary amputation.4-6
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doi:10.1016/j.jvs.2011.01.062RI is a frequently prevalent comorbidity in CLI pa-
ients.1-3 Presence of RI is associated with increased major
dverse events, mortality, and restenosis as well as with
ower technical success rates in patients undergoing percu-
aneous coronary artery intervention4 and below-the-knee
ndovascular interventions.4,5 Moreover, dialysis patients
xhibit a higher risk for limb loss after surgical revascular-
zation for PAD compared with patients with normal renal
unction.3 Finally, endovascular therapy was described to
e of limited clinical efficacy in PAD patients due to severe
alcifications of the pedal arteries.5
Although more specific data elucidating the impact of RI
re currently lacking, CLI patients with renal dysfunction are
requently excluded from clinical trials investigating novel
ndovascular treatment approaches. The purpose of the pres-
nt study was to scrutinize the impact of RI on clinical out-
omes of CLI patients undergoing endovascular revascular-
zation.
ATIENTS AND METHODS
Consecutive patients with chronic CLI undergoing
ndovascular revascularization presenting to a tertiary re-
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June 20111590 Willenberg et alferral center were followed prospectively over a 12-month
period. The center is responsible for peripheral vascular
service in a population of 1.5 million.
Recorded patient details comprised demographic char-
acteristics, risk factors and clinical presentation, imaging
studies, treatment modality, and prospective follow-up
data. Approval of the responsible ethical committee (Min-
istry of Health, Canton of Berne, Switzerland, KEK-Nr.
108/02) had been obtained before start of patient accrual.
The study was carried out according to the Declaration of
Helsinki6 and patients had given informed consent prior to
inclusion into the study.
Definition of CLI followed current consensus,7,8 ie, (1)
presence of ischemic rest pain for more than 2 weeks or
ischemic tissue loss, associated with (2) an absolute ankle
pressure 50 mm Hg or great toe pressure 30 mm Hg.
Patients with acute limb ischemia and with acute renal
failure were excluded. Patients were categorized into three
groups as either normal/mildly reduced renal function
(group 1), moderate renal dysfunction (group 2), and
severe renal dysfunction, including dialysis-dependent pa-
tients (group 3).1
Patient assessment was performed at baseline before
and at 2, 6, and 12 months after endovascular therapy.
Assessment consisted of complete noninvasive vascular
work-up, including measurements of systolic blood pres-
sure of both the anterior and posterior tibial arteries, calcu-
lation of ankle-brachial index (ABI), and oscillometric
reading. Repeated imaging implied duplex ultrasound in
case of suspected inflow (iliac and femoropopliteal) lesions
and repeated angiography in case of suspected infrapopli-
teal reobstruction with a clinical need to perform repeated
revascularization. In view of advanced age and comorbidi-
ties of CLI patients, a range of 3 weeks around each
scheduled study visit was tolerated. However, patients were
followed more frequently according to individual clinical
needs. Repeated imaging studies were limited to patients
where recurrent stenosis, occlusion, or additional arterial
lesions were suspected clinically or hemodynamically. Ex-
perienced vascular technicians performed all vascular labo-
ratory measurements. Wound management of ischemic
lesions was performed by specialized physicians and nurses
on our outpatient clinic. All patients were evaluated on a
case-by-case basis by a dedicated multidisciplinary vascular
board, including interventional angiologists, radiologists,
and vascular surgeons. This panel had been established
according to international recommendations7 and has been
convening since 1998 for daily conferences. Departmental
guidelines regarding optimal revascularization strategy
were continuously adapted to up-to-date recommenda-
tions,7,8 and a policy to treat patients with chronic CLI by
endovascular means whenever technically possible rather
than to operate was adopted from the beginning of the
accrual phase. Thereby, decisions were based on clinical
presentation, urgency of therapy, general condition of the
patient, including presence of limiting comorbidities as well
as anatomic distribution and morphologic nature of vascu-
lar lesions, availability of autologous veins, and access for pndovascular therapy. The same panel was involved in
reatment decisions during follow-up regarding the need
or repeated or delayed revascularizations and major ampu-
ations. Decisions on repeated revascularization were in-
ariably based on repeated vascular imaging in addition to
linical findings. During the study period, the consulting
hysicians and surgeons did not change within the team.
In cases of prohibitive lesion pattern, patient’s refusal,
r if the overall clinical situation suggested an expectant
ttitude, further procedure was restricted to pharmacologic
reatment ie, analgesic, antibiotic, and antiplatelet/anti-
hrombotic as well as lipid lowering, antihypertensive or
iabetes medication, and infrequently prostaglandins.9,10
Risk factor definitions. Arterial hypertension was as-
umed when measurement of arterial blood pressure ex-
eeded 140 mm Hg (systolic) and/or 90 mm Hg (dia-
tolic) at least on two different occasions or if the patient
as on antihypertensive medication.11
Hyperlipidemia was defined by a total serum choles-
erol level of 5 mmol/L, serum high-density lipoprotein
holesterol level of1mmol/L, or serum triglyceride level
f 2 mmol/L. Additionally, hyperlipidemia was assumed
f a patient was on lipid-lowering medication.11
Diabetes mellitus was defined by fasting blood sugar
evels 120 mg/dL, or HbA1c level 6%. In addition,
resence of diabetes mellitus was assumed if the patient
onsumed any hypoglycemic drugs.11 Coronary heart dis-
ases included ischemic pathologies as myocardial infarc-
ion (Q-wave or non-Q-wave MI), a history of angina
ectoris or the consumption of antianginal medication,
revious percutaneous or surgical coronary revasculariza-
ion, or positive exercise test. Cerebrovascular disease was
iagnosed in patients with known carotid artery disease and
istory of minor/major stroke or transient ischemic attack.
Current smoking habits were divided into either smok-
ng or nonsmoking. A smoking history (current or former
mokers) was established in patients who had 1 pack-year or
ore of tobacco use based on patient interview or chart
ocumentation.11
Patients were grouped according to level of renal func-
ion: normal or mildly reduced renal function (estimated glo-
erular filtration rate [eGFR],60mL/min/1.73m2),mod-
rate renal insufficiency (eGFR, 30-59mL/min/1.73m2), and
evere renal insufficiency (eGFR,30 mL/min/1.73 m2),
ncluding dialysis-dependent renal failure.3
Endpoint definitions. Endpoint definitions were in
ine with current reporting standards.12,13 Technical suc-
ess was defined as successful angioplasty with a residual
iameter reduction of30% on the procedural completion
ngiogram in at least two different projections. Sustained
linical improvement was defined as an upward shift of at
east one category on the Rutherford classification10 com-
ared with baseline to a level of claudication without re-
eated revascularization or unplanned amputation in sur-
iving patients.
Repeated revascularization was defined as any repeated
rocedure (endovascular or surgical) due to a problem
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Volume 53, Number 6 Willenberg et al 1591arising from the initially treated lesion as well as arising
remotely from the initial lesion.
Hemodynamic improvement was defined as an imme-
diate ABI improvement of 0.1 or to an ABI 0.9,
whereas sustained hemodynamic improvement was defined
accordingly but not allowing for repeated revascularization.
Moreover, oscillometric reading was used to determine
hemodynamic changes subsequent to intervention.14 Re-
sults from oscillometric readings were assessed semiquanti-
tatively as follows: (1) flat curve, (2) moderate amplitude,
and (3) dicrotic curve. A change from a flat curve at baseline
to a moderate amplitude or dicrotic curve was regarded as
hemodynamic success in patients with falsely elevated
ABI.15 Sustained hemodynamic improvement was defined
accordingly.
Amputations were considered major and thus regis-
tered if performed above the ankle. Conversely, limb sal-
vage was defined as absence of major amputation during
the observation period, ie, preservation of a functional
lower extremity. Thirty-day mortality was defined as deaths
from any cause within 1 month of the intervention.
Statistical analysis. Descriptive analyses of socio-
demographic characteristics were based on patient character-
istics at the time of the first intervention. Redo interventions
were excluded from the study. Demographic and clinical
characteristics of study population are reported as mean (
standard deviation [SD]) for continuous variables and as
number (percentage) for categorical variables.
Statistical analyses focused on impaired renal function
as a risk factor for distal PAD. Data analysis and stratifica-
tion, in regard to renal function, was performed in a
grouped (three categories, definitions see above)1 and in a
continuous fashion. A multivariable logistic regression was
used to analyze the impact of renal function on clinical
outcomes in CLI patients. Results are shown as relative risk
ratio with 95% confidence intervals (95% CIs). Cumulative
analysis of endpoints was assessed using Kaplan-Meier
curves.16 For estimates of cumulative mortality, patients
were uncensored in case of death; for all other analyses,
Table I. Demographic and risk factor data of 208 patients
to renal function
Total cohort
(208 patients)
N
(
Age, years (SD) 77.1 (9.6) 7
Men, n (%) 126 (60.6)
ABI, mean (SD) 0.36 (.29) 0
Creatinine (mg/dL), mean (SD) 1.39 (1.13) 0
Hyperlipidemia, n (%) 107 (51.4)
Coronary heart disease, n (%) 151 (72.6)
Cerebrovascular disease, n (%) 41 (19.7)
Arterial hypertension, n (%) 158 (76.0)
Diabetes mellitus, n (%) 121 (58.2)
Smoking, n (%) 100 (48.1)
ABI, Ankle-brachial index; n, number; RI, renal insufficiency; SD, standard
aOne-way analysis of variance (ANOVA).limbs were uncensored in case of target lesion revascular- wzation, minor or major amputation, and whenever clinical
mprovement was never reached or lost. A P value of .05
as considered statistically significant. All analyses were
erformed using the MedCalc Software (Version 11.2.1;
edCalc Software, Mariakerke, Belgium).
ESULTS
Between January 1999 and June 2004, a total of 208
onsecutive patients (218 limbs, mean age 77.1 9.5, 126
en) with CLI underwent endovascular revascularization
nd were enrolled in the prospective observational study.
ne hundred four patients of 208 (50%) had normal renal
unction or mild renal impairment, whereas 82/208
39.4%) had moderate and 22/208 (10.6%) had severe RI.
ithin the latter group, 16/22 (72.7%) patients were on
hronic hemodialysis. During this time period, 108 further
LI limbs (26%) were treated with a time delay or conser-
atively for various reasons, 85 (20%) limbs had undergone
urgical revascularization, and 16 (4%) limbs had under-
one primary amputation. Outcomes of these patients are
escribed elsewhere.17,18 Of note, renal function in pa-
ients undergoing conservative treatment (eGFR, 82.7
L/min; 95%CI, 71.7-91.7; SD, 49.2) was significantly
etter (P  .001) compared with that of patients from the
ercutaneous transluminal angioplasty group (eGFR, 71.0;
5% CI, 66.7-75.3; SD,  31.7). In contrast, patients
ndergoing surgical revascularization exhibited similar re-
al function (eGFR, 85.3 mL/min; 95% CI, 77.6-93.0;
D,  35.1) compared with patients from the percutane-
us transluminal angioplasty group (P  .25).
Demographics of 208 patients included in the present
tudy are illustrated in Table I. Anatomic levels of endovas-
ular procedures are specified in Table II. No significant
ifference was seen in technical success rates comparing
atients with normal renal function to those with moder-
te, and severe RI (95.2% vs 92.5% vs 100%; P  .36, by
nalysis of variance [ANOVA] test).
Clinical outcomes. Sustained clinical success after 2,
, and 12 months was 81.7%, 74.1%, and 51.5% in patients
ergoing endovascular treatment, categorized according
ild RI
atients)
Moderate RI
(82 patients)
Severe RI
(22 patients) P valuea
10.6) 80.2 (6.9) 72.5 (10.6) .004
70.2) 40 (48.8) 13 (59.1) .01
.26) 0.34 (.32) 0.38 (.32) .67
.24) 1.37 (.28) 4.1 (1.83) .001
49.0) 44 (53.7) 12 (54.5) .82
65.4) 66 (80.5) 17 (77.3) .12
24.0) 16 (19.5) 0 (0) .1
75.0) 63 (76.8) 17 (77.3) .9
59.6) 45 (54.9) 14 (63.6) .7
51.0) 35 (42.7) 12 (54.5) .48
tion.und
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patients with severe RI (P  .87, by log-rank; Fig 1).
Cumulative rates of repeated revascularization were
20.7%, 27.3%, and 46.4% in patients with normal renal
function, 21.1%, 37.5%, and 40.3% in patients with mod-
erate and 19%, 33.7%, and 45.7% in patients with severe RI
(P  .98, by log-rank; Fig 2) after 2, 6, and 12 months.
Noncumulative surgical and endovascular reintervention
rates are specified in Table III. Immediate hemodynamic
improvement according to ABI and oscillometric reading
did not differ among groups and was obtained in 72.2%,
79.1%, and 83.3% in patients with normal renal function,
moderate and severe RI, respectively (P  .39, by 2 test).
Accordingly, no differences were found among groups
regarding sustained hemodynamic improvement at 2, 6,
and 12 months (P  .07, by ANOVA test; Table III).
Minor amputations were necessary in 10.7%, 13.4%, and
20.2% of patients with normal renal function, respectively,
in 14.0%, 15.7%, and 17.9% with moderate and in 4.8%,
Table II. Anatomic level of angioplasty of 218 critically is
according to renal function
Total cohort
(218 limbs)
No/
(10
Anatomic level of angioplasty
Iliac, n (%) 32 (14.7) 18
Femoral, n (%) 147 (67.4) 71
Crural, n (%) 124 (56.9) 64
Stenting, n (%) 22 (10.1) 14
n, Number; RI, renal insufficiency; SD, standard deviation.
aOne-way analysis of variance (ANOVA).
Fig 1. Sustained clinical improvement in 218 criticall
RI, Renal insufficiency.9.5%, and 19.6% of patients with severe RI (P  .96, by cog-rank) after 2, 6, and 12 months. Accordingly, major
mputations were necessary in 9.9%, 18.2%, and 20.8% of
atients with normal renal function, in 9.9%, 22.6%, and
4% with moderate, and in 12.5%, 16.7%, and 21.1% of
atients with severe RI (P .83, by log-rank; Fig 3). A total
f 11 CLI patients (5.3%) died within 30 days of revascu-
arization (fatal myocardial infarction, n  4; fatal stroke,
 2; sepsis, n  2; tonsillar carcinoma, n  1; breast
ancer, n  1; multiorgan failure, n  1). Thirty-day
ortality rates in patients with normal, moderate, and
evere RI dysfunction were 4.6%, 5.8%, and 8.3%, respec-
ively (P  .76, ANOVA-test). Mortality rates at 2, 6, and
2 months were 8.4%, 17.4%, and 26.5% in patients with
ormal renal function, 9.6%, 17.6%, and 30.1% in patients
ithmoderate renal dysfunction, and 17.5, 26.6%, and 31.9%
n patients with severe RI (P .77, by log-rank; Fig 4).
Multivariate regression analysis. In multivariate
nalysis adjusted for age, gender, diabetes mellitus, arterial
ypertension, cigarette smoking, coronary heart disease,
ic limbs undergoing endovascular treatment, categorized
RI
s)
Moderate RI
(86 limbs)
Severe RI
(24 limbs) P valuea
) 13 (15.1) 1 (4.2) .30
) 61 (70.9) 15 (62.5) .42
) 44 (51.2) 16 (66.7) .43
) 8 (9.3) 0 (0.0) .17
emic limbs, categorized according to renal function.chem
mild
8 limb
(16.7
(65.7
(59.3
(13.0y ischerebrovascular disease, segment of endovascular revascu-
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severity (ischemic rest pain vs skin lesions) at baseline, it was
shown that creatinine clearance at baseline is an independent
predictor for increased mortality (hazard ratio [HR], 1.016;
95%CI, 1.001-1.031;P .036, byCox proportional hazards
regression).Moreover, age (HR, 1.12; 95%CI, 1.061-1.189;
P .0001) and cigarette smoking (HR, 3.14; 95%CI, 1.153-
8.55; P  .026) were identified as further independent pre-
dictors for higher mortality. In contrast, the presence of isch-
emic rest pain at baseline was associated with lower mortality
(HR, 0.115; 95%CI, 0.014-0.926; P .043) comparedwith
presence of ischemic skin ulcers. Renal function did not inde-
Fig 2. Target extremity revascularization in 218 c
function. RI, Renal insufficiency.
Table III. Postprocedural outcomes of 218 critically ische
according to renal function
Total coho
(218 limb
Noncumulative rates of repeated revascularization
at 1 year
Surgical, n (%) 32 (14.7
Endovascular, n (%) 48 (22.0
Ankle brachial index (ABI)
ABI at baseline, mean (SD) .36 (.3
ABI at 2 months, mean (SD) .71 (.3
ABI at 6 months, mean (SD) .63 (.3
ABI at 12 months, mean (SD) .62 (.2
Hemodynamic success
Postinterventional, n (%) 166 (76.1
At 2 months, n (%) 130 (59.6
At 6 months, n (%) 80 (36.7
At 12 months, n (%) 66 (30.3
ABI, Ankle-brachial index; n, number; RI, renal insufficiency; SD, standard
aOne-way analysis of variance (ANOVA).pendently influence sustained clinical improvement (P .45, py Cox proportional hazards regression), repeated revascular-
zation (HR, 1.0018; 95% CI, 0.992-1.0115; P .713) and
imb salvage (P  .83, by Cox proportional hazards regres-
ion).
ISCUSSION
The present series represents consecutive CLI patients
f a tertiary vascular center undergoing endovascular revas-
ularization. The aim of this study was to assess the impact
f RI on clinical outcomes after endovascular revasculariza-
ion. Moderate or severe RI was present in every second
lly ischemic limbs, categorized according to renal
limbs undergoing endovascular treatment, categorized
No/mild RI
(108 limbs)
Moderate RI
(86 limbs)
Severe RI
(24 limbs) P valuea
18 (16.7) 11 (12.8) 3 (12.5) .73
22 (20.4) 19 (22.1) 7 (29.2) .63
.38 (.3) .35 (.3) .35 (.3) .87
.74 (.3) .68 (.3) .64 (.1) .53
.69 (.3) .58 (.3) .62 (.3) .2
.62 (.2) .59 (.3) .75 (.2) .46
78 (72.2) 68 (79.1) 20 (83.3) .39
67 (62.0) 48 (55.8) 15 (62.5) .63
34 (31.5) 34 (39.5) 12 (50.0) .17
32 (29.6) 22 (25.6) 12 (50.0) .07
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June 20111594 Willenberg et alCLI patients in whom diabetes mellitus is highly prevalent
exhibit functional renal impairment.19
Technical success of endovascular revascularization was
achieved in more than 90% of patients in the present series
and did not differ comparing patients with and without RI
despite the oftentimes more complex and calcified obstruc-
tive lesion pattern in CLI patients with RI.20 Thus, our data
confirm results from various series describing primary tech-
nical success rates between 86% and 97% in the peripheral
Fig 3. Limb salvage rates in 218 critically ischemic lim
ficiency.
Fig 4. Survival of 208 critical limb ischemia (CLI) pa
insufficiency.arteries and underscores technical improvements of dedi- eated endovascular devices for endovascular infrageniculate
evascularization throughout the last years.21-25
The present study shows that sustained clinical success
uring 12-month follow-up is not influenced by renal
unction and thus supports the role of endovascular revas-
ularization in patients with CLI and even severe RI.26,27
urthermore, we saw no differences in both hemodynamic
mprovement andminor andmajor amputation rates after 1
ear comparing patients with normal renal function, mod-
tegorized according to renal function. RI, Renal insuf-
s, categorized according to renal function. RI, Renalbs, catientrate, and severe RI.
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Volume 53, Number 6 Willenberg et al 1595A recently published retrospective analysis of 123 limbs
in 111 patients with CLI undergoing tibial angioplasty
showed an overall amputation rate of 25%.19 In the sub-
group of patients with end-stage renal disease, the ampu-
tation rate increased to 46%. However, all other patients
with renal insufficiency not requiring dialysis showed an
amputation rate of 18% after 12 months, which is compa-
rable to our results in patients with RI independent of renal
disease stage. Of note, in contrast to the present study,
there was no further classification of the extent of func-
tional renal impairment in the latter publication.19 More-
over, in the retrospective series by Fernandez et al, presence
of RI and need for pedal intervention were associated with
impaired limb salvage.19 In fact, clinical efficacy of infra-
geniculate angioplasty was described to be limited in pa-
tients with end-stage renal disease due to severely diseased
pedal arteries.20 However, in the present series, inflow
angioplasty was required in a substantial subset of patients,
indicating that endovascular therapy in CLI patients is not
confined to infrageniculate angioplasty alone.28
Within a recently published meta-analysis, Albers and
colleagues analyzed published outcomes of 1314 surgical
revascularization procedures performed in 1272 lower
limbs of 1027 patients. In that series, 964 patients were
dialysis dependent, 58 had a renal transplant, and five had
RI not requiring dialysis.29 The 1-year pooled estimate for
limb salvage was 78.6%. Thus, the amputation rate ob-
served in our present series is well comparable with recent
reports on surgical revascularization in CLI patients with
RI.29,30
O’Hare analyzed 9932 patients undergoing surgical
revascularization for PAD in VA hospitals.3 In total, 11% of
patients in that study underwent major lower extremity
amputation within 1 year after surgical revascularization:
10% of patients with normal renal function, 11% of patients
with moderate RI, 12% of patients with severe RI, and 29%
of patients receiving dialysis. However, it remains unclear,
howmany patients underwent primary amputation without
attempting revascularization in this study. In contrast to
the findings by O’Hare, amputation rates after endovascu-
lar therapy in the present series were higher, whereas our
primary amputation rate of 4% is substantially lower com-
pared with other series reflecting our institutional policy of
aggressive revascularization attempts.31-34 Thus, one
might assume that in some patients, endovascular therapy
was probably attempted, although the anatomical situation
was rather unsuitable for any kind of revascularization, as
reflected in the 10% major amputation rate 2 months after
revascularization in the present study. Thus, our data indi-
cate that functional lower limb outcomes in CLI patients
undergoing endovascular revascularization are not inde-
pendently worsened by the presence of RI.
Patient survival was poor in our series confirming prior
observations regarding the dismal systemic prognosis of
CLI patients.17,20 About every third patient had died after
1 year of follow-up. In the above-cited meta-analysis by
Albers, 1-year mortality in CLI patients with RI undergo-
ing surgical revascularization was comparable to that of our reries and might reflect a higher burden of systemic arterial
alcification in RI patients.29 Of note, patient mortality was
he only endpoint in the present series independently influ-
nced by renal function. In fact, estimated patient mortality
uring follow-up is crucial for power analysis and study
rotocol design for prospective interventional trials. There-
ore, high mortality in CLI patients with RI oftentimes
eads to their exclusion from clinical trials. In the present
eries, the hazard ratio of creatinine clearance for increased
ortality was 1.016, thereby being lower compared with
hat of age (HR, 1.12) and cigarette smoking (HR, 3.14).
ccording to findings from the present study, however,
urviving patients may benefit from functional limb out-
omes independent of renal function at baseline. Thus, it
ay be the sickest CLI patients in which a clinical benefit of
ovel endovascular technologies can be demonstrated.
One further important factor potentially hampering the
nclusion of patients with RI in endovascular revasculariza-
ion trials is the fear of additional contrast material exposure
uring follow-up angiography. Angiographic follow-up is
ftentimes warranted in studies investigating novel endo-
ascular devices,12,13 especially after revascularization of
elow-the-knee arteries where duplex ultrasound has sub-
tantial limitations.35 The volume of contrast medium used
or intra-arterial angiography usually reflects a clinical com-
romise between patient safety and the need to optimize
mage quality. Iodine concentration and volume of contrast
aterial are risk factors for contrast-induced nephropathy,
lthough definitive cut-off doses have not been estab-
ished.36 According to previously published consensus
iew, administration of a contrast volume lower than 100
L is preferable in patients with an eGFR 60 mL/min
er 1.73 m2.36 However, both the precise eGFR cut-off
alue and the amount of contrast material beyond which
pplication of contrast medium leads to a substantial dete-
ioration of pre-existing RI is currently unpredictable for
ndividual patients. Moreover, the impact of specific pre-
entive measures such as prehydration and administration
f prostanoids or N-acetylcysteine aimed at minimizing
enal functional worsening subsequent to contrast admin-
stration cannot be predicted for each individual patient.
owever, it has to be noted that serial selective angiogra-
hy of an endovascular target lesion can be performed using
0 to 20 mL of contrast material.
Several limitations of the present study need to be
ddressed. First, the included number of subjects with
evere renal insufficiency is limited and weakens both the
ower of our statistical analysis and the strength of our
onclusion for this subgroup. Second, our study did not
ontain prospective assessment of arterial patency of in-
luded patients. As outlined above, repeated revasculariza-
ion was performed if deemed necessary based on clinical
nd hemodynamic findings and did not differ significantly
mong the three groups. Third, this article contains results
rom 208 patients with 218 limbs. Thus, observations are
ot independent in 10 patients (4.8%). However, when
ecalculating our data for 208 limbs and 208 patients after
andom removal of one limb in 10 patients, results remain
11
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1
1
2
2
2
2
2
2
2
2
2
2
3
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June 20111596 Willenberg et almuch the same (data not shown). Finally, we did not
maintain further evaluation of renal function and its
changes compared with baseline during follow-up. There-
fore, the impact of contrast material on renal function
during follow-up cannot be provided.
In summary, functional lower limb outcomes were not
impacted by the presence of RI, while mortality rates were
higher in the present series of CLI patients undergoing
endovascular therapy. Thus, categorical exclusion of these
patients from prospective endovascular CLI trials should be
reconsidered, since the benefit of novel endovascular treat-
ment concepts might be of particular clinical importance in
this challenging patient population. Further prospective
studies are warranted to define appropriate thresholds be-
yond which renal functional impairment limits relevant
patient outcomes.
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